Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | TRHR | P34981 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000430 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9TRHR | |
| SCHEMBL1000429 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9TRHR | |
| Bromide SCHEMBL7325613 | 0.99 | DPP4 (0.43) | DPP4DPP8DPP9TRHR | |
| Bromide SCHEMBL5735593 | 0.99 | DPP4 (0.43) | DPP4DPP8DPP9TRHR | |
| Bromide SCHEMBL7325997 | 0.99 | DPP4 (0.43) | DPP4DPP8DPP9TRHR | |
| SCHEMBL10454953 | 0.96 | TRHR (0.43) | DPP4DPP8DPP9TRHR | |
| SCHEMBL10454951 | 0.96 | TRHR (0.43) | DPP4DPP8DPP9TRHR | |
| SCHEMBL5734357 | 0.91 | DPP4 (0.44) | DPP4DPP8DPP9 | |
| SCHEMBL4595209 | 0.91 | DPP4 (0.44) | DPP4DPP8DPP9 | |
| SCHEMBL4595206 | 0.91 | DPP4 (0.44) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194443-B1 | NOVEL PEPTIDES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-30 | — | — | EP | claimed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| EP-1962952-A2 | DRY MATRICES AS DRUG RESERVOIRS IN ELECTROTRANSPORT APPLICATIONS | Alza Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076083-A2 | DRY MATRICES AS DRUG RESERVOIRS IN ELECTROTRANSPORT APPLICATIONS | ALZA CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1061936-A4 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | UNIV GEORGETOWN (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1061936-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999040931-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0647133-A4 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. | AFFYMAX TECH NV (AN) | 1997-10-29 | — | — | EP | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | DPP4 193/4885DPP8 274/4885DPP9 318/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | DPP4 525/4885DPP8 644/4885DPP9 996/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | DPP4 525/4885DPP8 644/4885DPP9 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.